<DOC>
	<DOCNO>NCT01519960</DOCNO>
	<brief_summary>This parallel group , open label study evaluate safety efficacy Pegasys ( peginterferon alfa-2a ) versus untreated control child ( age 3 year &lt; 18 year baseline ) HBeAg positive chronic hepatitis B . Children without advanced fibrosis without cirrhosis randomize 2:1 treatment Group A , receive Pegasys 45-180 mcg subcutaneously weekly 48 week , untreated control Group B . Children advance fibrosis assign treatment group C receive 48 week treatment Pegasys . Children untreated control Group B experience seroconversion 48 week randomization may enter Switch Arm receive 48 week Pegasys treatment . This offer available 1 year follow 48 week randomization . Anticipated time study treatment 48 week . All subject follow 5 year end treatment ( A , C , Switch ) /principal observation ( B ) period .</brief_summary>
	<brief_title>A Study Pegasys ( Peginterferon Alfa-2a ) Versus Untreated Control Children With HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female patient , 3 year &lt; 18 year age baseline Positive HBsAg 6 month Positive HBeAg detectable HBV DNA screen Negative antiHBs antiHBe screen A liver biopsy obtain within past 2 year prior baseline ( 6 month end previous therapy hepatitis B ) confirm presence advanced fibrosis exclude cirrhosis Compensated liver disease ( ChildPugh Class A ) Elevated serum alanine transferase ( ALT ) Normal thyroid gland function screen Subjects cirrhosis Subjects must receive investigational drug license treatment antiHBV activity within 6 month baseline . Subjects expect need systemic antiviral therapy provide study time participation study also exclude Known hypersensitivity peginterferon Positive test result screen hepatitis A , hepatitis C , hepatitis D HIV infection History evidence medical condition associate chronic liver disease chronic hepatitis B History evidence bleed esophageal varix Decompensated liver disease ( e.g . ascites , ChildPugh Class B C ) History immunologically mediate disease Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>